TP53 and fatty liver disease: To confirm that reduced P53 ubiquitination and its abnormal accumulation contribute to GSN deficiency‐induced hepatic steatosis, we treated Gsn−/−mice with the P53 inhibitor PFT via intraperitoneal injection (Figure S15A, Supporting Information).